---
title: Common and complex diseases
description: The Common and Complex Disease Use Case are focussing on the development of a national-focussed decision support software based on Polygenic Risk Scores (PRS) results. 
page_id: common-complex-diseases
---
The Common and Complex Disease Use Case are focussing on the development of a national-focussed decision support software based on Polygenic Risk Scores (PRS) results. 

The expected outcomes from the 1+MG initiative for the Common and Complex Disease Use Cases are to:

* Generate the first results in the Pharmcogenomics (PGx) field in major common diseases and also for likely drug response
* Develop/Implement a platform for decsion making support systems for polygenic risk scores
* Create a Proof of Concept for the entire pipeline

## [Common and complex diseases and pharmacogenomics: policy brief for 2022-2027](https://ec.europa.eu/newsroom/dae/redirection/document/93728) <span class="badge badge-dark">Recommended<i class="fa-solid fa-thumbs-up"></i></span>
* Integrate PRS into healthcare comes with multiple challenges including ELSI considerations, it’s clinical utility, public awareness and acceptance and it’s physical implementation into infrastructure and resources. Based on this WG10 created the following Policy Brief detailing it’s expectations of each of its signatory countries and its needs from Policy in order to responsibly implement this field of genomics. 



**We are still working on the content for this page.** If you are interested in adding to the page, then:

[Feel free to contribute](how_to_contribute){: class="btn btn-primary btn-lg rounded-pill"}

This is a community-driven website, so contributions are welcome! You will, of course, be listed as a contributor on the page.
